Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nooreen Rubin"'
Autor:
Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel
Supplementary Figure S1. Potency against FGFR family and kinome selectivity. Supplementary Figure S2. Kinases with a cysteine at the equivalent position to Cys552 in FGFR4. Supplementary Figure S3. MALDI Mass Spectrometry of FGFR4. Supplementary Figu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8961190ae57361a2b45e2b8293c97f7
https://doi.org/10.1158/2159-8290.22530420
https://doi.org/10.1158/2159-8290.22530420
Autor:
Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel
Supplementary Methods and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bdbee434896ada0f2bffee6775eee2
https://doi.org/10.1158/2159-8290.22530417
https://doi.org/10.1158/2159-8290.22530417
Autor:
Oleg Schmidt-Kittler, Michael Sheets, Yoon-Koo Kang, Chandrasekhar V. Miduturu, Richard D. Kim, Andy Boral, Joseph L. Kim, Nooreen Rubin, Neil Bifulco, Emily Rozsahegyi, Cori Ann Sherwin, Megan A. Hatlen, Natasja Brooijmans, Marion Dorsch, Hongliang Shi, Beni B. Wolf, Klaus P. Hoeflich, Christoph Lengauer, Timothy J. Guzi
Publikováno v:
Cancer Discovery. 9:1686-1695
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of human cancer on
Autor:
Beni B. Wolf, Cori-Ann Sherwin, Natasja Brooijmans, Christoph Lengauer, Hongliang Shi, Megan A. Hatlen, Michael Sheets, Neil Bifulco, Emily Rozsahegyi, Chandra Miduturu, Yoon-Koo Kang, Marion Dorsch, Richard D. Kim, Nooreen Rubin, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Andy Boral, Joseph L. Kim, Timothy J. Guzi
Publikováno v:
Molecular Cancer Therapeutics. 18:A118-A118
When on-target resistance mutations occur in response to potent and selective therapeutics, the target is often considered a validated driver of disease. Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide whose drivers re
Autor:
Lily I. Pao, Quentin J. Baca, Clifford A. Lowell, Kenneth D. Swanson, David E. Golan, Nooreen Rubin, Takashi Matozaki, Benjamin G. Neel, Francis J. Alenghat
Publikováno v:
Journal of cell science, vol 125, iss Pt 22
Alenghat, FJ; Baca, QJ; Rubin, NT; Pao, LI; Matozaki, T; Lowell, CA; et al.(2012). Macrophages require Skap2 and Sirpα for integrin-stimulated cytoskeletal rearrangement. Journal of Cell Science, 125(22), 5535-5545. doi: 10.1242/jcs.111260. UCSF: Retrieved from: http://www.escholarship.org/uc/item/1xx8h9bk
Alenghat, FJ; Baca, QJ; Rubin, NT; Pao, LI; Matozaki, T; Lowell, CA; et al.(2012). Macrophages require Skap2 and Sirpα for integrin-stimulated cytoskeletal rearrangement. Journal of Cell Science, 125(22), 5535-5545. doi: 10.1242/jcs.111260. UCSF: Retrieved from: http://www.escholarship.org/uc/item/1xx8h9bk
Macrophages migrate to sites of insult during normal inflammatory responses. Integrins guide such migration, but the transmission of signals from integrins into the requisite cytoskeletal changes is poorly understood. We have discovered that the hema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc6d1b146fcb7538ec6e4073f4819de9
https://escholarship.org/uc/item/1xx8h9bk
https://escholarship.org/uc/item/1xx8h9bk
Autor:
Lucian Dipietro, Natasja Brooijmans, Christoph Lengauer, Weifan Weng, Joseph Kim, Nicolas Stransky, Timothy J. Guzi, Nooreen Rubin, Margit Hagel, Christopher Winter, Neil Bifulco, Mike Sheets, Chandra Miduturu
Publikováno v:
Cancer Research. 74:LB-324
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Chemotherapy has proven ineffective, and Sorafenib remains the only approved targeted drug with no second or third line treatment options. Sorafenib slows the growt